IRAK4-IN-17 (Compound 5) is a highly potent inhibitor of IRAK4, exhibiting an impressive IC50 value of 1.3 nM [1]. This compound is particularly valuable for research focused on large B-cell lymphoma (DLBCL) [1].

IRAK4-IN-17 (0.7-40.1 μM; 72 h) selectively suppresses OCI-LY10 and TMD8 cells with MYD88 L265P mutation [1]. IRAK4-IN-17 (0.3-10 μM; 2 h) inhibits the viability of DLBCL cells by targeting IRAK4 signaling [1]. Cell Cytotoxicity Assay [1] Cell Line: OCI-LY10, TMD8, Ramos and HT cells Concentration: 0.7-40.1 μM Incubation Time: 72 hours Result: Suppressed OCI-LY10 and TMD8 cells with MYD88 L265P mutation (IC 50 =0.7 μM and 1.2 μM, respectively), but not Ramos and HT cell lines with WT MYD88 (IC 50 =11.4 μM and 40.1 μM, respectively). Western Blot Analysis [1] Cell Line: OCI-LY10 and TMD8 cells Concentration: 0.3, 1, 3 and 10 μM Incubation Time: 2 hours Result: Inhibited the phosphorylation of IRAK4 and the downstream molecules, IKKβ and NF-κB transcription factor (p65) in OCI-LY10 and TMD8 cells.